ESC Premium Access

Applying evidence in practice: appropriate use of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in the cardiology clinic.

Presentation

About the speakers

Doctor Jacob Allan Udell

Women's College Hospital, Toronto (Canada)
8 presentations
0 follower

Professor Naveed Sattar

BHF Glasgow Cardiovascular Research Centre, Glasgow (United Kingdom of Great Britain & Northern Ireland)
30 presentations
2 followers

5 more presentations in this session

Welcome and introduction - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.

Speaker: Professor N. Marx (Aachen, DE)

Thumbnail

Evidence-based approaches to reducing premature cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease.

Speaker: Professor D. McGuire (Dallas, US)

Thumbnail

Advancing the standard of care in patients with type 2 diabetes and established cardiovascular disease: how can we improve patient outcomes? .

Speaker: Professor N. Marx (Aachen, DE) Professor D. McGuire (Dallas, US) Doctor J. Udell (Toronto, CA) Professor S. Verma (Toronto, CA) Professor N. Sattar (Glasgow, GB)

Thumbnail

Exploring the effects of SGLT2 inhibition in ongoing trials.

Speaker: Professor S. Verma (Toronto, CA)

Thumbnail

Summary and close - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.

Speaker: Professor N. Marx (Aachen, DE)

Thumbnail

Access the full session

Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice

Speakers: Doctor J. Udell, Professor N. Sattar, Professor N. Marx, Professor D. McGuire, Professor N. Marx...
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk